MAINZ BIOMED B.V. EO 1 news, videos and press releases
For more news please use our advanced search feature.
MAINZ BIOMED B.V. EO 1 - More news...
MAINZ BIOMED B.V. EO 1 - More news...
- EQS-News: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
- Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
- EQS-News: Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
- Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
- EQS-News: Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
- Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
- EQS-News: Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
- Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
- EQS-News: Mainz Biomed Expands into Switzerland with labor team w
- Mainz Biomed Expands into Switzerland with labor team w
- EQS-News: Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
- Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
- EQS-News: Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
- Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
- EQS-News: Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
- Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
- Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- EQS-News: Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
- Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
- EQS-News: Mainz Biomed Announces Stock Split
- Mainz Biomed Announces Stock Split
- EQS-News: Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
- Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
- EQS-News: Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
- Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
- Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
- EQS-News: Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
- EQS-News: Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
- Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
